摘要
目的探讨不同剂量瑞舒伐他汀对卒中后认知障碍(非痴呆)(PSCIND)患者循环相关miRNA的影响。方法纳入2018年1月至2020年3月于我院住院治疗的64例PSCIND患者,随机分为低剂量组、高剂量组,各32例。另纳入20例不耐受他汀类药物或对他汀类药物过敏的PSCIND患者为对照组。分别于入组时(T0)、治疗后3个月(T1)检测三组患者血清认知相关miRNA(miR-124、miR-134和miR-138)水平,并评估认知状态(MoCA评分和MMSE评分)。结果高剂量组ΔMoCA(U=2.140,P=0.032)和ΔMMSE(U=2.041,P=0.041)均高于对照组。高剂量患者T1时MoCA较T0时明显升高(t=2.107,P=0.039)。T1时低剂量组miR-134(t=2.255,P=0.027)、高剂量组miR-124(t=3.473,P<0.001)、miR-134(t=3.951,P<0.001)和miR-138(t=2.309,P=0.024),以及对照组miR-124(t=2.155,P=0.035)水平较T0时明显下降。T1时高剂量组患者miR-134水平明显高于对照组(t=2.098,P=0.039)。低剂量组、高剂量组和对照组在ΔmiR-124(t_(低vs.对)=2.953,P=0.004;t_(高vs.对)=5.724,P<0.001;t_(低vs.高)=3.765,P<0.001)、ΔmiR-134(t_(低vs.对)=2.988,P=0.004;t_(高vs.对)=4.785,P<0.001;t_(低vs.高)=3.113,P=0.003)和ΔmiR-138(t_(高vs.对)=4.024,t_(低vs.高)=3.431,P<0.001)均存在明显差异,以高剂量组最为明显。相关性分析提示,高剂量瑞舒伐他汀治疗与ΔmiR-134相关性最大(r=-0.304,P=0.005)。结论瑞舒伐他汀有助于改善PSCIND患者认知功能水平以及下调认知障碍相关miRNA浓度。
Objective To evaluate the effects of different doses of rosuvastatin on circulation-related miRNAs in PSCIND patients.Methods A total of eighty-four PSCIND patients were enrolled in this study:20 PSCIND patients with intolerance or allergy to statin were in control group and the others were divided into low-dose group and high-dose group.The levels of miRNAs(miR-124,miR-134 and miR-138)and levels of cognitive stage(MoCA score and MMSE score)were measured at two time points:on admission(T0)and at 3 months after treatment(T1).Results The T1 levels ofΔMoCA(U=2.140,P=0.032)andΔMMSE(U=2.041,P=0.041)in high-dose group were higher than those in control group.The levels of MoCA in high-dose group were higher than those at T0(t=2.107,P=0.039).The T1 levels of miR-134(t=2.255,P=0.027)in low-dose group,and miR-124(t=3.473,P<0.001),miR-134(t=3.951,P<0.001)and miR-138(t=2.309,P=0.024)in high-dose group and miR-124(t=2.155,P=0.035)in control group were reduced compared with those at T0.The T1 levels of miR-134(t=2.098,P=0.039)in high-dose group were higher than those in control group.TheΔmiR-124(t_(L vs.C)=2.953,P=0.004;t_(H vs.C)=5.724,P<0.001;t_(L vs.H)=3.765,P<0.001),ΔmiR-134(t_(L vs.C)=2.988,P=0.004;t_(H vs.C)=4.785,P<0.001;t_(L vs.H)=3.113,P=0.003)andΔmiR-138(t_(H vs.C)=4.024,t_(L vs.H)=3.431,P<0.001)presented significant difference among the groups,especially in high-dose group.Correlation analysis showed that high dose statin treatment was most related withΔmiR-134(r=-0.304,P=0.005).Conclusion Rosuvastatin contributes to improving cognitiving impairment and reduce the levels of cognitive impairment-related miRNAs.
作者
孙晓旭
孙弋
尹国明
苏明君
李强
SUN Xiao-xu;SUN Yi;YIN Guo-ming;SU Ming-jun;LI Qiang(Department of Pharmaceutical Supply,Chifeng College Affiliated Hospital,Chifeng 024005,China;Department of Clinical Pharmacy,Chifeng College Affiliated Hospital,Chifeng 024005,China;Department of Neurology,Chifeng College Affiliated Hospital,Chifeng 024005,China)
出处
《实用药物与临床》
CAS
2021年第12期1082-1086,共5页
Practical Pharmacy and Clinical Remedies
